Ligand Pharmaceuticals (STU:LGDN) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:LGDN Ligand Pharmaceuticals Inc STU:LGDN
74 GF Score
Price €260.00
GF Value €153.80
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ligand Pharmaceuticals Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:LGDN
74GF Score
Ligand Pharmaceuticals Inc STU:LGDN
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ligand Pharmaceuticals (STU:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €260.00 is trading 69.1% above its estimated GF Value™ of €153.80. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:LGDN:

  • Interest Received:
  • GF Value™: €153.80 vs. price of €260.00 (69.1% above fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the STU:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ligand Pharmaceuticals Business Description

Other Exchanges LGND:USALGDN:Germany
Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
74GF Score

Get the complete analysis for STU:LGDN

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€260.00
Price
€153.80
GF Value